A Foundation of Clinical Evidence
The Corvia Atrial Shunt is the most clinically studied atrial shunt for the reduction of Left Atrial Pressure (LAP) in HFpEF/HFmrEF patients. Over 750 patients have been studied to date and multiple studies are ongoing.
Implanted patient-years of follow-up1
Years post-implant for the longest ongoing Corvia Atrial Shunt patients1
Clinical Evidence Summary: Pilot Study, REDUCE LAP-HF, REDUCE LAP-HF I
Immediate and significant PCWP reduction of 3-5mmHG with clinical improvement sustained over 12 months.2
The Corvia Atrial Shunt demonstrated consistent, durable results in nearly 100 patients across 3 studies.
of RV failure
out to 5 years3
Patency @ 1 year4-6
Cases of implant removal, closure, or thrombosis through 8 years7
- Unpublished data on file at Corvia Medical. Data as of January 14, 2022.
- Feldman T, Mauri L, Kahwash, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial. Circ. 2018;137(4):364-375.
- Unpublished data compiled from Corvia Pilot Study (n=11), REDUCE LAP-HF (n=64), and REDUCE LAP-HF I (n=22 randomized to treatment). Data on file at Corvia Medical.
- Kaye DM, Hasenfuß G, Neuzil P, et al. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure with Preserved Ejection Fraction. Circ Heart Fail. 2016 Dec; 9(12).
- Unpublished data from Corvia Pilot Study (n=11). Data on file at Corvia Medical.
- Shah S J, Feldman T, Ricciardi MJ, et al. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 Oct 1;3(10):968-977.
- Unpublished data compiled from all Corvia implants as of September 1, 2021. Data on file at Corvia Medical.